Study of Blood Tests to Detect Metastatic Uveal Melanoma Early

What this Trial Is About

Uveal melanoma is the most common primary eye tumor in adults. Although local treatments can be effective, patients often die from metastatic disease. Researchers are studying whether certain serum biomarkers can help detect metastases earlier than current imaging methods, potentially leading to earlier treatment and improved survival. This observational study aims to assess if changes in biomarker levels can predict metastases before they are visible on scans. Participants will be monitored as a single group without any experimental treatments. The study observes changes in specific blood markers over time to determine if these can signal the development of metastatic uveal melanoma. This approach may identify metastases up to 12 months before imaging can detect them, allowing for earlier intervention. During the study, participants will have their blood drawn regularly to measure biomarker levels. Researchers will compare these levels to imaging results to see if biomarker changes correspond with metastases diagnosis. The main outcome is whether a significant increase in biomarker levels can be linked to metastases detected by imaging up to a year earlier. The study is observational and does not involve any treatment participants will continue their standard care throughout. The study may continue until December 2040.

Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma